Rising Pharma Holding, Inc. FDA Record
- Latest inspection NAI · Nov 3, 2023
- No warning letters matched by name
Rising Pharma Holding, Inc. has 13 FDA recalls, 1 inspection, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Rising Pharma Holding, Inc." is on file.
- Latest recall
- D-0724-2026 · Class II · Jul 13, 2026
- Latest inspection
- Nov 3, 2023 · NAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 13 | Nov 11, 2026 (checked Nov 15, 2026, unchanged) | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 1 | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions | 0 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Rising Pharma Holding, Inc.: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 0 | 0 | 0 | 2 | 0 |
| 2025 | 0 | 0 | 0 | 2 | 0 |
| 2024 | 0 | 0 | 0 | 8 | 0 |
| 2023 | 1 | 0 | 0 | 1 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 0 | 0 | 0 | 0 | 0 |
| 2018 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 0 | 0 | 0 | 0 | 0 |
Reviewing Rising Pharma Holding, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Rising Pharma Holding, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0724-2026 | Class II | Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for… | Jul 13, 2026 |
| D-0384-2026 | Class II | Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for… | Mar 3, 2026 |
| D-0029-2026 | Class II | Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only… | Oct 7, 2025 |
| D-0277-2025 | Class II | Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising… | Mar 5, 2025 |
| D-0189-2025 | Class II | Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising… | Dec 30, 2024 |
| D-0190-2025 | Class II | Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC… | Dec 30, 2024 |
| D-0188-2025 | Class II | Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC… | Dec 30, 2024 |
| D-0106-2025 | Class II | Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC… | Nov 19, 2024 |
| D-0105-2025 | Class II | Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising… | Nov 19, 2024 |
| D-0107-2025 | Class II | Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and… | Nov 19, 2024 |
| D-0599-2024 | Class III | Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories, Inc… | Jun 24, 2024 |
| D-0541-2024 | Class III | Pregabalin Capsules 50mg, 1000-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings… | May 16, 2024 |
| D-0222-2024 | Class II | buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only… | Dec 29, 2023 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Nov 3, 2023 | East Brunswick, NJ | Drugs | No Action Indicated (NAI) | 3015784623 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3015784623 | East Brunswick, NJ | 1 | Nov 3, 2023 |
Rising Pharma Holding, Inc. and the FDA: common questions
Has Rising Pharma Holding, Inc. received an FDA warning letter?
No FDA warning letter addressed to the name "Rising Pharma Holding, Inc." is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.
Has Rising Pharma Holding, Inc. received an FDA Form 483?
FDA has not published a Form 483 for "Rising Pharma Holding, Inc." in its reading room. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Rising Pharma Holding, Inc.?
The most recent FDA inspection on file ended Nov 3, 2023 at East Brunswick, NJ and was classified NAI. FDA has 1 inspection of Rising Pharma Holding, Inc. on file.
Has Rising Pharma Holding, Inc. had an FDA recall?
Yes. Rising Pharma Holding, Inc. has 13 FDA recalls on record. The most recent started Jul 13, 2026.
Need more than this page shows? Ask about Rising Pharma Holding, Inc. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.